Bezmialem Vakif University
Istanbul, Fatih/Istanbul, 34093, Turkey (Türkiye)
NCT Number: NCT05807100
The aim of this study is to investigate the effect of the current periodontal status on the progression rate of AD.
Looking for future studies?
Notify Me50 year–89 year
All sexes
Observational
Istanbul, Fatih/Istanbul, 34093, Turkey (Türkiye)
Although much is known about its pathogenesis, Alzheimer's disease (AD) is still a terminal disease. For this reason, the correct evaluation and treatment of the risk factors of the disease gains importance in the prevention of the disease. Chronic inflammation, such as periodontal disease, can speed up the onset and progression of AD. The study aimed to investigate the relationship between periodontal status and the rate of progression of dementia in individuals diagnosed with Alzheimer's disease.
In this study, 90 individuals with AD, who were classified as Stage I, Stage II, and Stage III according to the Clinical Dementia Rating Scale. Baseline and 6th month cognitive status assessments of participants who met the inclusion criteria were performed in the Department of Neurology using SMMT. At the 6th month control appointment in the Neurology Department, the participants were referred to the Periodontology Department for oral examinations.
In the Periodontology Department, dental anamnesis of the patients was taken and intraoral examinations were performed. Periodontal examination of all existing teeth of all participants with at least one remaining tooth (excluding third molars) with a Williams-marked periodontal probe (Hu-Friedy, Chicago, Illinois, USA) and all molars and maxillary first premolars with Nabers probe (PQ2N, Hu-Friedy, Chicago, Illinois, USA) was performed and records %P (plak percentage), %BOP (percentage bleeding on probing), CAL (clinical attachment level), PPD (probing pocket depth). The position of the gingival margin and PPD were measured at six sites/teeth (including/excluding third molars). The CAL was then calculated from these measurements. In 2017, periodontal status was determined according to the decisions of the World Workshop on Periodontal and Peri-implant Diseases and Classification of Conditions. The current occlusal relationship status of all patients was evaluated using the Eichner Index and classified as Type 1 (A1-A2-A3-B1) , Type 2 (B2-B3) and Type 3 (B4-C1-C2-C3).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Cognitive status assessment was done with Standardized Mini Mental Test.
Cognitive status assessment was done with Standardized Mini Mental Test.
Other names: Periodontal Examination: Toothed/edentulous condition, occlusal relationship type and periodontal status were evaluated by periodontal examination.
Time frame: Baseline and 6th month
The baseline SMMT score was recorded. After 6 months, the 6th month SMMT score was recorded. Change in SMMT score at 6 months= Baseline SMMT score-6th SMMT score.
Time frame: Baseline
The stage of Alzheimer's disease was determined according to the clinical dementia rating scale.
Stage I: Mild, Stage II: Moderate, Stage III: Severe.
Time frame: Baseline
The gender distribution of Alzheimer's patients was divided into male and female.
Time frame: Baseline
Ages of Alzheimer's patients were determined.
Time frame: Baseline
The current systemic conditions of Alzheimer's patients were evaluated and those with diabetes mellitus and cardiovascular disease were determined.
Time frame: 6th month
Alzheimer patients were evaluated according to the presence and absence of active periodontal disease.
Time frame: 6th month
It is an index that shows the amount of microbial dental plaque on the teeth.
Time frame: 6th month
Bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus.
Time frame: 6th month
The distance from the gingival margin to pocket base.
Time frame: 6th month
The clinical attachment level is the distance between the enamel-cementum junction and the gingival sulcus.
Time frame: 6th month
The number of teeth present in Alzheimer's patients was determined.
Time frame: 6th month
Alzheimer's patients were classified according to the Eichner Index (A1-A2-A3-B1-B2-B3-B4-C1-C2-C3). They were evaluated according to their occlusal relationship status and classified as Type 1, Type 2 and Type 3.
Time frame: between baseline and -6th month
C-Reactive Protein (CRP) is a protein found in blood plasma whose circulating concentration is associated with inflammation.
Time frame: between baseline and -6th month
It refers to the percentage of circulating neutrophils to total white blood cells.
Time frame: between baseline and -6th month
It refers to the percentage of circulating lymphocytes to total white blood cells.
Time frame: between baseline and -6th month
It is demonstrates the number of neutrophils in the peripheral blood.
Time frame: between baseline and -6th month
It is demonstrates the number of lymphocytes in the peripheral blood.
Time frame: between baseline and -6th month
Neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing the absolute number of neutrophils by absolute number of lymphocytes.
Time frame: between baseline and -6th month
Mean platelet volume (MPW) is a measure of the average size of the platelets.
Time frame: between baseline and -6th month
Platelet distribution width (PDW) reflects the variability in platelet size distribution.
Bezmialem Vakif University
Other
Analyzing the Relationship Between Periodontal Health Status and Alzheimer's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07069244
Alzheimer Disease, Biomarkers / Blood
Bolu, Turkey (Türkiye)
View Trial DetailsNCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT03933696
Alzheimer Disease, Brain Diseases
New Brunswick, New Jersey, United States
View Trial DetailsNCT05584241
Alzheimer Disease, Amnestic Mild Cognitive Disorder
Ann Arbor, Michigan, United States
View Trial Details